Co-Diagnostics Ships TB Testing Equipment to India for Clinical Trials

Co-Diagnostics, Inc. (CODX) has officially commenced shipping its PCR Pro instruments and tuberculosis (TB) test kits to its Indian joint venture, CoSara Diagnostics. This move is intended to launch clinical studies that align with the latest World Health Organization (WHO) recommendations for near-point-of-care molecular testing. The diagnostic platform utilizes the company's proprietary tongue swab technology, which simplifies the sample collection and preparation process. These trials represent a critical step in the company's efforts to penetrate the Indian healthcare market, which faces a significant TB burden. By adhering to WHO standards, Co-Diagnostics aims to validate its technology for broader international commercialization. Investors view this development as a positive milestone in the company's product pipeline and global expansion strategy.

Sources:prnewswire.comstocktitan.netbenzinga.comidealens.cothinkglobalhealth.orgmorningstar.comuk.investing.commedicaldevice-network.compharmabiz.cominvesting.comstreetinsider.com